VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Receives Consensus Rating of “Reduce” from Brokerages

Shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN) have earned a consensus rating of “Reduce” from the five brokerages that are presently covering the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation and four have assigned a hold recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $0.95.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of VistaGen Therapeutics in a research report on Wednesday, June 3rd.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. ADAR1 Capital Management LLC purchased a new position in VistaGen Therapeutics during the 2nd quarter valued at approximately $79,000. Luminus Management LLC bought a new stake in VistaGen Therapeutics in the 4th quarter worth approximately $232,000. BlackRock Inc. purchased a new stake in shares of VistaGen Therapeutics during the 2nd quarter worth approximately $78,000. Two Sigma Investments LP raised its holdings in shares of VistaGen Therapeutics by 223.5% during the 3rd quarter. Two Sigma Investments LP now owns 289,409 shares of the company’s stock worth $1,027,000 after acquiring an additional 199,958 shares in the last quarter. Finally, Millennium Management LLC boosted its position in shares of VistaGen Therapeutics by 853.0% during the 4th quarter. Millennium Management LLC now owns 197,045 shares of the company’s stock valued at $130,000 after acquiring an additional 176,369 shares during the last quarter. Institutional investors own 78.39% of the company’s stock.

VistaGen Therapeutics Trading Down 1.6%

VTGN traded down $0.00 on Monday, hitting $0.24. 106,702 shares of the company’s stock traded hands, compared to its average volume of 2,150,461. The company’s 50 day simple moving average is $0.34 and its 200-day simple moving average is $0.50. The firm has a market cap of $10.65 million, a price-to-earnings ratio of -0.14 and a beta of 0.41. VistaGen Therapeutics has a one year low of $0.20 and a one year high of $5.14.

VistaGen Therapeutics (NASDAQ:VTGN) last posted its quarterly earnings results on Friday, August 14th. The company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.06. VistaGen Therapeutics had a negative return on equity of 152.59% and a negative net margin of 2,702.64%.The business had revenue of $1.48 million during the quarter, compared to the consensus estimate of $0.50 million. As a group, equities analysts anticipate that VistaGen Therapeutics will post -1.32 EPS for the current fiscal year.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.